We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take ...

Neurocrine Biosciences, the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help ...

Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "CRENESSITY, a novel oral corticotropin-releasing factor type 1 receptor antagonist, has demonstrated the potential to achieve two key ...

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company ...

In both children and adults, the drug allows for decreasing glucocorticoid dosing to physiological levels while still ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a biopharmaceutical company with a market capitalization of $11.9 billion and impressive revenue growth of 21.7% over the last twelve months ...

In patients with classic congenital adrenal hyperplasia, crinecerfont conferred meaningful reductions in glucocorticoid dose ...

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a $11.9 billion biopharmaceutical company with impressive revenue growth of 21.7% over the last twelve months, has presented new Phase 3 study ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a $11.9 billion biopharmaceutical company with impressive revenue growth of 21.7% over the last twelve months, has presented new Phase 3 ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a biopharmaceutical company with a market capitalization of $11.9 billion and impressive revenue growth of 21.7% over the last twelve months, ...